Drug Trial Radar · NCT06319794
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
Last checked: Nov 19, 2026Latest source record: Jul 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Apr 2, 2024
Primary completion
Jun 24, 2025
Study completion Jun 24, 2025
Sponsor
- Lead sponsor
- TORQURIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to evaluate efficacy and safety of bimiralisib gel treatment for treatment of actinic keratosis (AK) on the face and/or scalp and/or back of hands
Conditions
- Actinic Keratosis
Interventions
BimiralisibDrug
Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 2 weeks
BimiralisibDrug
Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in AK lesions as measured by achieving an Investigator Global Assessment (IGA) score of 0 or 1Time frame: Baseline, Day 43 (Treatment Arm A), Day 57 (Treatment Arm B)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University Hospital Basel / Department of Dermatology
Basel, Switzerland
CHUV centre hospitalier universitaire vaudois / Department of Dermatology and Venereology
Lausanne, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.